Alkem Laboratories (ALKEM.NS) Stock Price
Alkem Laboratories Price
Over the last 16 years Alkem Laboratories grew revenue by 16.1% annually, reaching 147.12 B INR. Earnings per share have grown at 15.3% per year over the last 16 years. For Alkem Laboratories, the net margin of 15.6% is broadly stable versus 15.7% a few years ago. At today's price the dividend yield works out to roughly 0.98%. The payout ratio is around 31% of earnings. The dividend has grown at 12.5% per year over the past 10 years. The consensus 12-month price target for Alkem Laboratories is 6,007.80 INR, about 15.3% above where the stock trades today. Of 27 analysts, 15 rate the stock a buy — an overall Buy consensus.
Alkem Laboratories stock price
Alkem Laboratories business model & stock analysis
Frequently asked questions about Alkem Laboratories
The business model of Alkem Laboratories Ltd revolves around the manufacturing and marketing of pharmaceutical products. As a leading Indian pharmaceutical company, Alkem Laboratories focuses on developing, producing, and distributing a wide range of generic and branded drugs across various therapeutic segments. With a strong emphasis on research and development, Alkem Laboratories aims to consistently bring innovative and affordable healthcare solutions to patients globally. By adhering to stringent quality standards and regulatory requirements, the company strives to maintain its reputation for delivering safe, effective, and high-quality medications. Alkem Laboratories Ltd is committed to improving healthcare accessibility and contributing to a healthier society.
Alkem Laboratories Ltd is primarily active in the pharmaceutical industry.
The main competitors of Alkem Laboratories Ltd in the market are Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, and Torrent Pharmaceuticals Ltd.
Alkem Laboratories Ltd. is a renowned pharmaceutical company with a rich history and background. Established in 1973, Alkem has consistently shown remarkable growth and has become one of India's leading pharmaceutical enterprises. The company is primarily engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical products for both domestic and international markets. Alkem Laboratories Ltd. has earned a stellar reputation for its high-quality products, state-of-the-art manufacturing facilities, and extensive research and development capabilities. With a strong focus on innovation and compliance with global quality standards, Alkem Laboratories Ltd. continues to make a significant impact in the healthcare industry, contributing to the overall wellness and patient care.
Alkem Laboratories Ltd has achieved several significant milestones throughout its journey. The company expanded its operations globally by establishing subsidiaries and offices in multiple countries. It received various certifications and accreditations, including the US FDA approvals for several of its manufacturing facilities. Alkem Laboratories Ltd has consistently focused on research and development, leading to the successful launch of innovative and affordable pharmaceutical products. Additionally, the company has fostered strong partnerships with renowned global pharmaceutical companies, enabling it to expand its product portfolio. Alkem Laboratories Ltd continues to demonstrate its commitment to excellence and is regarded as a leading player in the pharmaceutical industry.
Alkem Laboratories Ltd is primarily present in multiple countries and regions worldwide. Some of the key areas where Alkem operates include India, the United States, Europe, Latin America, and various Asian and African countries. With a strong global presence, Alkem Laboratories has established a robust network and continually expands its reach to cater to diverse markets.
Alkem Laboratories Ltd represents values of integrity, quality, and innovation. The company prioritizes ethical business practices and strives for excellence in product manufacturing and distribution. Alkem Laboratories believes in delivering high-quality healthcare solutions to improve patients' lives. The company's corporate philosophy revolves around continuously investing in research and development, fostering a culture of learning and growth, and maintaining strong relationships with healthcare professionals and stakeholders. By upholding these values, Alkem Laboratories positions itself as a trusted and reliable pharmaceutical company in the market.
Analysts currently set an average price target of 5,966.79 INR for the Alkem Laboratories stock (median: 6,007.80 INR), implying +14.5 % versus the latest price. The consensus is based on 27 analyst ratings.
27 analysts currently rate the Alkem Laboratories stock: 15 recommend buying, 9 holding and 3 selling.
Converted at the current exchange rate, the Alkem Laboratories share trades at 48.86 EUR (5,209.00 INR).
The Alkem Laboratories share (ALKEM.NS) is listed on 2 stock exchanges, including: NSE (Indien) (ALKEM.NS).
Alkem Laboratories Ltd is a leading pharmaceutical company based in India and operates globally. The company is involved in various divisions, including generics, branded generics, OTC products, APIs, and biosimilars. The generics division of Alkem Laboratories Ltd is one of the largest in India, covering a wide range of therapeutic areas. The company also produces a variety of branded generics under the name "Alkem's Brand," including dermatology, gastroenterology, cardiology, neurology, and gynecology products. Alkem Laboratories Ltd also offers a range of OTC products, including antacids, pain relievers, cough and cold products, vitamins, and minerals. They have a strong presence in this market segment and their products are available in India and other countries. Additionally, the company is involved in API production, which serve as key intermediates for drug manufacturing. They have a wide range of APIs used in various therapeutic areas. Alkem Laboratories Ltd is also involved in the development of biosimilars, with a strong pipeline in various stages of development, covering areas such as oncology, autoimmune diseases, and diabetes. The company has a strong presence in India and operates globally, with a focus on providing high-quality and affordable medicines that meet customer needs. They invest in research and development to continually develop new products and have a strong distribution infrastructure to quickly bring products to market and strengthen their presence. Overall, Alkem Laboratories Ltd aims to offer a wide range of products and divisions to meet market demand, with a strong team and modern infrastructure positioning them to expand their market presence in India and globally. The business model of Alkem Laboratories Ltd is focused on providing high-quality and affordable medicines that meet customer needs.
The revenue of Alkem Laboratories is 147.12 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Alkem Laboratories is 23.02 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Alkem Laboratories is currently 27.06. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alkem Laboratories stock.
The price-to-sales ratio (P/S) of Alkem Laboratories is currently 4.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alkem Laboratories stock.
The Eulerpool Quality Score for Alkem Laboratories is 8/10.
The ISIN of Alkem Laboratories is INE540L01014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Alkem Laboratories is ALKEM.NS. The ticker symbol is used to trade Alkem Laboratories shares on the stock exchange.
Alkem Laboratories stock
Alkem Laboratories Peer Group
Alkem Laboratories Ticker
Alkem Laboratories FIGI
All fundamentals and in-depth analysis of Alkem Laboratories
Our stock analysis for Alkem Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alkem Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.